Nuclear DNA helicase II is recruited to IFN-α-activated transcription sites at PML nuclear bodies

Journal of Cell Biology

Volumn 158, Issue 3, 2002, Pages 463-473

  Fuchsová, Beata ^a   Novák, Petr ^b   Kafková, Jarmila ^c   Hozák, Pavel ^a,d,e  

^a Institute of Experimental Medicine   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^c INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Interferon; Nuclear DNA helicase II; PML nuclear body; RNA helicase A; RNA polymerase II

Indexed keywords

ALPHA INTERFERON; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA HELICASE 2; HELICASE; RNA; RNA HELICASE; RNA HELICASE A; RNA POLYMERASE II; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CELL NUCLEUS INCLUSION BODY; CELL SPECIFICITY; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME BINDING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MASS SPECTROMETRY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RNA SYNTHESIS; TRANSCRIPTION REGULATION;

ADENOSINE TRIPHOSPHATASES; AMANITINS; AUTOIMMUNE DISEASES; BLOOD PROTEINS; CELL NUCLEUS STRUCTURES; DNA; DNA HELICASES; EUKARYOTIC CELLS; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; MACROMOLECULAR SUBSTANCES; MICROSCOPY, ELECTRON; NEOPLASM PROTEINS; NUCLEAR PROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; PRECIPITIN TESTS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 0036327097     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.200202035     Document Type: Article

References (58)

1. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein
2. Identification of a novel nuclear domain
3. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha
4. Identification and characterization of a leukocyte-specific component of the nuclear body
5. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia
6. Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA
7. The transcription coactivator cbp is a dynamic component of the promyelocytic leukemia nuclear body
8. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest
9. The PML gene encodes a phosphoprotein associated with the nuclear matrix
10. Transcriptional activation by BRCAI
11. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: Dihydrolipoamide acetyltransferase
12. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
13. Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein
14. The PML-retinoic acid receptor alpha translocation converts the receptor from an inhibitor to a retinoic acid-dependent activator of transcription factor AP-1
15. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling
16. A novel macromolecular structure is a target of the promyelo-cyte-retinoic acid receptor oncoprotein
17. Molecular cloning of a new interferon-induced PML nuclear body-associated protein
18. Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp 100 and promyelocytic leukemia protein (PML)
19. Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors
20. IFN enhance expression of Sp 100, an autoantigen in primary biliary cirrhosis
21. Coupling antibodies to protein A beads
22. Replication factories and nuclear bodies: The ultrastructural characterization of replication sites during the cell cycle
23. PML is critical for ND 10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1
24. Visualization of focal sites of transcription within human nuclei
25. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor
26. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion
27. The PML growth-suppressor has an altered expression in human oncogenesis
28. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
29. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body
30. The acute promyelocytic leukaemia-associated PML gene is induced by interferon
31. Human RNA helicase A is homologous to the maleless protein of Drosophila
32. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation
33. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937
34. Immunoprecipitation of proteins under nondena-turing conditions
35. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
36. PML, a growth suppressor disrupted in acute promyelocytic leukemia
37. RNA helicase A mediates association of CBP with RNA polymerase II
38. The DNA helicase activity of BLM is necessary for the correction of the genomic instability of bloom syndrome cells
39. In vivo degradation of RNA polymerase II largest subunit triggered by alpha-amanitin
40. Inhibition of RNA synthesis by actinomycin D: Characteristic dose-response of different RNA species
41. Regional specialization in human nuclei: Visualization of discrete sites of transcription by RNA polymerase III
42. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1
43. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element
44. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp 100 by PIC1/SUMO-1
45. A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies
46. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis
47. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
48. Transcriptional repression by the promyelocytic leukemia protein
49. CREB-binding protein (CBP)/p300 and RNA polymerase II colocalize in transcriptionally active domains in the nucleus
50. Role of PML in cell growth and the retinoic acid pathway
51. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells
52. Nuclear dot antigens may specify transcriptional domains in the nucleus
53. Pre-mRNA and mRNA binding of human nuclear DNA helicase II (RNA helicase A)
54. Molecular cloning of the gene encoding nuclear DNA helicase II. A bovine homologue of human RNA helicase A and Drosophila Mle protein
55. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation
56. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and TI 8 oncoproteins
57. The transcriptional role of PML and the nuclear body
58. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis